Volition reports 95% detection rate for early-stage cancers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Volition Announces Detection of Over 95% of Early-Stage Cancers
March 25, 2026 8:17 AM EDTBlinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificityCapture-Seq Targets $36 Billion TAM in Early Cancer Detection and MRD.
HENDERSON, Nev., March 25, 2026 /PRNewswire/ --Â VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture-Seq technology.
... More